Can You Take Quetiapine with Mirtazapine?

Severity assessment

Moderate. Concomitant use may increase the risk of serotonin syndrome and QT prolongation.

Mechanism (plain English)

Mirtazapine and quetiapine both affect brain chemicals, particularly serotonin. Mirtazapine increases serotonin levels, and quetiapine, while primarily an antipsychotic, also has some serotonergic activity. When taken together, there's a risk of too much serotonin in the brain, leading to a condition called serotonin syndrome. Additionally, both medications can affect the heart's electrical activity, specifically prolonging the QT interval, which can lead to a dangerous irregular heartbeat. Quetiapine also has anticholinergic properties, which can lead to additive central nervous system (CNS) depression when combined with other agents.

Evidence level

Case-report-supported. The risk of serotonin syndrome is supported by case reports, such as one involving an 85-year-old woman who developed serotonin syndrome after an increase in quetiapine dosage while also taking mirtazapine and other serotonergic medications [Miyamatsu, 2021; Kohen, 2007]. The risk of QT prolongation is generally recognized for both drugs individually and as a class, with warnings in product information.

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): No pair-specific public advisory found. Applicable product information for Quetiapine (SEROQUEL XR) warns that quetiapine may have additive cardiovascular effects in combination with other drugs known to prolong the QT interval. It also notes that QT prolongation and torsade de pointes have been reported during post-marketing use in cases of quetiapine overdose and in patients with risk factors. [TGA ARTG ID 138920, Product Information]
• MHRA / NICE (UK): No specific guidance found for this exact pair. General guidance for both drugs advises caution with other CNS depressants and drugs that prolong the QT interval.
• FDA / CDC (US): The FDA label for Seroquel (quetiapine) states that the use of quetiapine should be avoided in combination with other drugs that are known to prolong QTc. [FDA Seroquel Label]
• EMA (Europe): No specific guidance found for this exact pair. General guidance for both drugs advises caution with other CNS depressants and drugs that prolong the QT interval.

Clinical risk factors that elevate the danger

• Pre-existing cardiac conditions: Patients with congenital long QT syndrome, other cardiac diseases, or a history of arrhythmias are at higher risk for QT prolongation.
• Electrolyte disturbances: Conditions like hypokalemia (low potassium) and hypomagnesemia (low magnesium) can increase the risk of QT prolongation.
• Concomitant use of other serotonergic agents: Taking other medications that increase serotonin levels (e.g., SSRIs, SNRIs, MAOIs) alongside mirtazapine and quetiapine significantly increases the risk of serotonin syndrome.
• Concomitant use of other CNS depressants: Alcohol, sedating antihistamines, antispasmodics, and other neuroleptics can enhance the CNS depressant effects of quetiapine and mirtazapine.
• Quetiapine overdose: Overdoses of quetiapine have been associated with QT prolongation and torsade de pointes.
• Elderly patients: Older individuals may be more susceptible to adverse effects due to altered metabolism and increased likelihood of polypharmacy and underlying health conditions.

What a patient should be told

• Risk of serious side effects: Taking mirtazapine and quetiapine together can increase the risk of two potentially serious conditions: serotonin syndrome (too much serotonin in the brain) and an irregular heartbeat (QT prolongation).
• Do not stop suddenly: Do not stop taking either medication or change your dose without talking to your doctor or pharmacist first. Suddenly stopping can worsen your condition or cause withdrawal symptoms.
• Warning signs: Be aware of symptoms like confusion, agitation, sweating, shivering, muscle stiffness or twitching, fast heartbeat, or dizziness. These could be signs of serotonin syndrome or an irregular heartbeat.
• Discuss alternatives: Talk to your doctor or pharmacist about all other medications you are taking, including over-the-counter drugs, supplements, and herbal remedies. They can help determine if this combination is right for you or if safer alternatives exist.
• Urgent care triggers: Seek immediate medical attention if you experience severe dizziness, fainting, palpitations, shortness of breath, or seizures.

Top 3 sources (with full citation)

1. Drugs.com. Interactions between Mirtazapine and Quetiapine. Available at: https://www.drugs.com/drug-interactions/mirtazapine-with-quetiapine-1640-0-1979-0.html?professional=1
2. Miyamatsu, Y., Tanizaki, R. (2021) "Serotonin syndrome triggered by increasing the dose of quetiapine" Clinical practice and cases in emergency medicine, 5, p. 365-366. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10909073/
3. U.S. Food and Drug Administration. Seroquel (quetiapine fumarate) Tablets. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020639s072lbl.pdf

Notes for the reviewing pharmacist

While the interaction between mirtazapine and quetiapine is classified as moderate, the potential for serious adverse events like serotonin syndrome and QT prolongation warrants careful consideration. The risk of serotonin syndrome appears to be primarily supported by case reports, suggesting it may be rare but significant when it occurs, especially in elderly patients or those on multiple serotonergic agents. The QT prolongation risk is a class effect for both drugs, and additive effects are a concern. Pharmacists should emphasize patient education regarding warning signs and the importance of not self-adjusting doses. Close monitoring for cardiac and neurological symptoms is crucial, particularly in patients with pre-existing risk factors or those initiating or escalating doses. Awareness of the potential for additive CNS depression with other agents is also important. The lack of specific pair-focused advisories from some regulators highlights the need for clinical judgment based on individual patient profiles and general drug class warnings.

Source metadata JSON

{
  "pair": "mirtazapine + quetiapine",
  "severity": "Moderate",
  "evidence_level": "Case-report-supported",
  "source_urls": "https://www.drugs.com/drug-interactions/mirtazapine-with-quetiapine-1640-0-1979-0.html?professional=1;https://pmc.ncbi.nlm.nih.gov/articles/PMC10909073/;https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020639s072lbl.pdf"
}